Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
35 studies found for:    " June 27, 2012":" July 27, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" June 27, 2012":" July 27, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Positive Change Agents Program-Tanzania (Evaluation)
Condition: HIV Infection
Intervention: Behavioral: Appreciative Inquiry Change Agents (CA) program (NAMWEZA)
2 Unknown  BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection
Condition: HIV
Intervention: Drug: efavirenz
3 Completed A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Condition: HIV Infections
Interventions: Drug: Doravirine;   Drug: Efavirenz;   Drug: TRUVADA®
4 Unknown  A Couple-Based Relationship Strengthening HIV Intervention for Young Parents
Condition: HIV
Interventions: Behavioral: Relationship Strengthening HIV Prevention Intervention;   Behavioral: Parenting Program Intervention
5 Active, not recruiting Trends of Morbidity and Mortality Among Thai HIV-infected and HIV-uninfected Patients: a Five-year Prospective Cohort Study
Conditions: HIV Infection;   Healthy
Intervention:
6 Completed Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics
Condition: HIV Infections
Intervention: Drug: FTC 200 mg/TDF 300 mg fixed-dose combination tablet
7 Completed Mobile Phone Technology for Prevention of Mother-to-Child Transmission of HIV: Acceptability, Effectiveness, and Cost
Conditions: HIV;   HIV Infections;   AIDS;   Antiretroviral Therapy
Interventions: Behavioral: Control;   Behavioral: Intervention
8 Unknown  Enhancing Ugandan HIV-Affected Child Development With Caregiver Training
Condition: HIV
Interventions: Behavioral: MISC;   Behavioral: UCOBAC
9 Recruiting Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Malawi
Condition: HIV
Interventions: Drug: Standard of Care prophylaxis;   Drug: Chloroquine (CQ) prophylaxis
10 Completed Atazavanir/Ritonavir-based HAART in Children
Condition: HIV
Intervention: Drug: boosted atazanavir (ATV/r)
11 Unknown  Evaluation of Use of Clinical Decision Support System in HIV Care in Resource Constrained Settings
Condition: HIV
Interventions: Other: EMR Only;   Other: EMR+CDSS
12 Enrolling by invitation Addressing Proven Factors in HIV Prevention for Latino Youth
Conditions: HIV;   Sexually Transmitted Infections
Interventions: Behavioral: audio-CD parent education;   Behavioral: health and success parent and school
13 Completed Abacavir and Lamivudine PK in Children
Condition: HIV
Interventions: Drug: abacavir;   Drug: 3TC
14 Completed MARCH Renal Substudy
Conditions: Proteinuria;   HIV
Interventions: Drug: arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors;   Drug: Arm 2 boosted protease inhibitors and maraviroc;   Drug: Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc
15 Completed Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services
Condition: HIV
Intervention: Drug: 1% tenofovir gel
16 Active, not recruiting Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744 10 mg;   Drug: GSK1265744 30 mg;   Drug: GSK1265744 60 mg;   Drug: Efavirenz 600 mg;   Drug: Rilpivirine 25 mg;   Drug: Placebo;   Drug: Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
17 Completed Relative Bioavailability Study of GSK1265744 Formulations
Condition: Infections, Human Immunodeficiency Virus and Hepatitis
Interventions: Drug: GSK1265744 Na Salt Tablets;   Drug: GSK1265744 Free Acid Nanomilled Capsules;   Drug: GSK1265744 Free Acid Micronized Capsules
18 Completed Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine
Condition: HIV
Interventions: Drug: Tenofovir (TFV) Alone Vaginal Tablet;   Drug: Emtricitabine (FTC) Alone Vaginal Tablet;   Drug: TFV and FTC Combined Vaginal Tablet;   Drug: Placebo Vaginal Tablet
19 Enrolling by invitation Bone Health and Vitamin D Status
Conditions: Osteopenia;   Vitamin D Deficiency;   HIV Infection
Intervention:
20 Completed Safety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost Vaccination
Conditions: Tuberculosis;   HIV
Interventions: Biological: MVA85A;   Biological: Candin;   Biological: BCG Vaccine SSI

   Previous Page Studies Shown (1-20) Next Page (21-35) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.